Form 4 for RLMD RELMADA THERAPEUTICS, INC.
Accepted 2024-09-11 00:00:00 ET · period of report 2024-09-09 · accession 0001213900-24-077791 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-11 | 2024-09-09 | RLMD | Kelly Paul Edward | Dir | P - Purchase | $2.59 | +25.0K | 212.3K | +13% | +$64.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-09 | P | A | 25,000 | $2.59 | 212,295 | D | — | — | (F1) The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. (F2) Purchase prices range from $2.50 to $2.64 per share, inclusive. |